Heron Therapeutics(US:HRTX) Globenewswire·2026-01-09 14:29Core Insights - Heron Therapeutics, Inc. reported preliminary, unaudited net revenue for Q4 and full-year 2025, indicating growth driven by its Acute Care franchise products, ZYNRELEF and APONVIE [1][2] Financial Performance - The company achieved net revenue of approximately $40.5 million for Q4 2025, with ZYNRELEF contributing approximately $12.5 million, APONVIE approximately $3.8 million, CINVANTI approximately $22.9 million, and SUSTOL approximately $1.3 million [7] - For the full year 2025, net revenue reached approximately $154.9 million, with ZYNRELEF showing a quarter-over-quarter revenue increase of about 35% compared to Q3 2025 [7] Product Information - ZYNRELEF is the first extended-release dual-acting local anesthetic approved for postoperative pain management, demonstrating significant efficacy in reducing pain and opioid use post-surgery [3] - APONVIE is a neurokinin 1 receptor antagonist for the prevention of postoperative nausea and vomiting, approved by the FDA in September 2022 and commercially available since March 2023 [5] - CINVANTI is indicated for the prevention of chemotherapy-induced nausea and vomiting, utilizing an IV formulation of aprepitant [8] Company Overview - Heron Therapeutics focuses on developing and commercializing therapeutic innovations aimed at improving patient care, leveraging advanced science and patented technologies [11]